Search

Your search keyword '"Shimbo, Taiju"' showing total 24 results
Start Over Author "Shimbo, Taiju"
24 results on '"Shimbo, Taiju"'

1. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial)

Author

Kondo, Keisaku, Matsusaka, Satoshi, Ishihara, Soichiro, Horie, Hisanaga, Uehara, Keisuke, Oguchi, Masahiko, Murafushi, Keiko, Ueno, Masashi, Mizunuma, Nobuyuki, Shimbo, Taiju, Kato, Daiki, Okuda, Junji, Hashiguchi, Yojiro, Nakazawa, Masanori, Sunami, Eiji, Kawai, Kazushige, Yamashita, Hideomi, Okada, Tohru, Ishikawa, Yuichi, Fujii, Masashi, and Nakajima, Toshifusa

Published
2019
Full Text
View/download PDF

2. KORTUC, a novel hydrogen peroxide‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer

Author

Shimbo, Taiju, primary, Yoshida, Ken, additional, Nakata, Mio, additional, Kobata, Kazuma, additional, Ogawa, Takashi, additional, Kihara, Ayaka, additional, Sato, Chikara, additional, Hori, Akihiro, additional, Takeno, Satoshi, additional, Yoshioka, Hiroto, additional, Akiyama, Hironori, additional, and Nihei, Keiji, additional

Published
2023
Full Text
View/download PDF

6. Effect of a lead block on alveolar bone protection in image-guided high-dose-rate interstitial brachytherapy for tongue cancer: Using model-based dose calculation algorithms to correct for inhomogeneity

Author

Akiyama, Hironori, primary, Yoshida, Ken, additional, Takenaka, Tadashi, additional, Kotsuma, Tadayuki, additional, Masui, Koji, additional, Monzen, Hajime, additional, Sumida, Iori, additional, Tsujimoto, Yutaka, additional, Miyao, Mamoru, additional, Okumura, Hiroki, additional, Shimbo, Taiju, additional, Takegawa, Hideki, additional, Murakami, Naoya, additional, Inaba, Koji, additional, Kashihara, Tairo, additional, Takácsi-Nagy, Zoltán, additional, Tselis, Nikolaos, additional, Yamazaki, Hideya, additional, Tanaka, Eiichi, additional, Nihei, Keiji, additional, and Ariji, Yoshiko, additional

Published
2022
Full Text
View/download PDF

10. High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report

Author

Nakata, Mio, primary, Yoshida, Ken, additional, Shimbo, Taiju, additional, Yoshikawa, Nobuhiko, additional, Yoshioka, Hiroto, additional, Hori, Akihiro, additional, Sato, Chikara, additional, Uesugi, Yasuo, additional, Kogata, Yuhei, additional, Masui, Koji, additional, Murakami, Naoya, additional, Kashihara, Tairo, additional, Akiyama, Hironori, additional, Tselis, Nikolaos, additional, Ohmichi, Masahide, additional, and Nihei, Keiji, additional

Published
2020
Full Text
View/download PDF

11. A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer

Author

Yoshida, Ken, Kotsuma, Tadayuki, Akiyama, Hironori, Yamazaki, Hideya, Takenaka, Tadashi, Masui, Koji, Tsujimoto, Yutaka, Murakami, Naoya, Uesugi, Yasuo, Shimbo, Taiju, Yoshikawa, Nobuhiko, Yoshioka, Hiroto, Nakata, Mio, Arika, Takumi, Takaoka, Yuji, Tanaka, Eiichi, Tselis, Nikolaos, Yoshida, Ken, Kotsuma, Tadayuki, Akiyama, Hironori, Yamazaki, Hideya, Takenaka, Tadashi, Masui, Koji, Tsujimoto, Yutaka, Murakami, Naoya, Uesugi, Yasuo, Shimbo, Taiju, Yoshikawa, Nobuhiko, Yoshioka, Hiroto, Nakata, Mio, Arika, Takumi, Takaoka, Yuji, Tanaka, Eiichi, and Tselis, Nikolaos

Abstract

Purpose: Tongue edema is a potential cause of treatment target underdosage in high-dose-rate interstitial brachytherapy (HDR-ISBT) of mobile tongue cancer. To prevent such edema-associated alteration of dosimetry, we developed a special silicon device. In this report we communicate our initial experience with two mobile tongue cancer patients whom we treated using this new device. Material and methods: The device consists of silicone tubes with a fixed width and scalable length depending on tongue size. These tubes are lined and fixed like a palisade, allowing the device to be used also as a template. The device is placed next to the lateral border of the tongue and on the floor of the mouth. In addition, a vinyl template can be placed on the dorsal tongue surface with both devices combined for implantation guidance. Between June and August 2012, two patients with locally confined tongue cancer were treated. Results: Between June and August 2012, two mobile tongue cancer patients classified as cT2N0M0 were treated with HDR-ISBT using the silicone device. They underwent ISBT as monotherapy with fractional doses of 6.0 Gy up to a total physical dose of 54.0 Gy. The D90 (CTV) values of both patients were 6.3 Gy and 6.6 Gy and the D2cc (mandible) values were 3.4 Gy and 2.6 Gy, respectively. At present, both patients remain without local disease recurrence at 60 and 56 months after ISBT, respectively. Conclusions: The described silicone device has the potential to prevent underdosage to the treatment target related to tongue edema. It has been shown to be safe and easy to implement.

Published
2019

12. A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer

Author

Yoshida, Ken, primary, Kotsuma, Tadayuki, additional, Akiyama, Hironori, additional, Yamazaki, Hideya, additional, Takenaka, Tadashi, additional, Masui, Koji, additional, Tsujimoto, Yutaka, additional, Murakami, Naoya, additional, Uesugi, Yasuo, additional, Shimbo, Taiju, additional, Yoshikawa, Nobuhiko, additional, Yoshioka, Hiroto, additional, Nakata, Mio, additional, Arika, Takumi, additional, Takaoka, Yuji, additional, Tanaka, Eiichi, additional, and Tselis, Nikolaos, additional

Published
2019
Full Text
View/download PDF

13. Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases

Author

Yoshida, Ken, primary, Yamazaki, Hideya, additional, Kotsuma, Tadayuki, additional, Akiyama, Hironori, additional, Takenaka, Tadashi, additional, Masui, Koji, additional, Yoshioka, Yasuo, additional, Uesugi, Yasuo, additional, Shimbo, Taiju, additional, Yoshikawa, Nobuhiko, additional, Yoshioka, Hiroto, additional, Arika, Takumi, additional, Tanaka, Eiichi, additional, and Narumi, Yoshifumi, additional

Published
2017
Full Text
View/download PDF

15. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial)

Author

Matsusaka, Satoshi, primary, Ishihara, Soichiro, additional, Kondo, Keisaku, additional, Horie, Hisanaga, additional, Uehara, Keisuke, additional, Oguchi, Masahiko, additional, Murofushi, Keiko, additional, Ueno, Masashi, additional, Mizunuma, Nobuyuki, additional, Shimbo, Taiju, additional, Kato, Daiki, additional, Okuda, Junji, additional, Hashiguchi, Yojiro, additional, Nakazawa, Masanori, additional, Sunami, Eiji, additional, Kawai, Kazushige, additional, Yamashita, Hideomi, additional, Okada, Tohru, additional, Ishikawa, Yuichi, additional, Nakajima, Toshifusa, additional, and Watanabe, Toshiaki, additional

Published
2015
Full Text
View/download PDF

16. Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer

Author

Yoshida, Ken, primary, Yamazaki, Hideya, additional, Nakamura, Satoaki, additional, Masui, Koji, additional, Kotsuma, Tadayuki, additional, Akiyama, Hironori, additional, Tanaka, Eiichi, additional, Yoshikawa, Nobuhiko, additional, Uesugi, Yasuo, additional, Shimbo, Taiju, additional, Narumi, Yoshifumi, additional, and Yoshioka, Yasuo, additional

Published
2015
Full Text
View/download PDF

17. A phase I/II study of S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma (JACCRO CC-04: SHOGUN trial).

Author

Watanabe, Toshiaki, primary, Matsusaka, Satoshi, additional, Ishihara, Soichiro, additional, Kondo, Keisaku, additional, Horie, Hisanaga, additional, Uehara, Keisuke, additional, Oguchi, Masahiko, additional, Murofushi, Keiko, additional, Ueno, Masashi, additional, Mizunuma, Nobuyuki, additional, Kato, Daiki, additional, Hashiguchi, Yojiro, additional, Shimbo, Taiju, additional, Okuda, Junji, additional, Nakazawa, Masanori, additional, Sunami, Eiji, additional, Kawai, Kazushige, additional, Yamashita, Hideomi, additional, Okada, Tohru, additional, and Ishikawa, Yuichi, additional

Published
2014
Full Text
View/download PDF

20. Patients’ subjective evaluation of early and late sequelae in patients with breast cancer irradiated with short fractionation for breast conservation therapy: comparison with conventional fractionation

Author

Inomata, Taisuke, primary, Narabayashi, Isamu, additional, Inada, Yuki, additional, Shimbo, Taiju, additional, Takahashi, Masatsugu, additional, Tatsumi, Toshiaki, additional, Uesugi, Yasuo, additional, Kariya, Shinji, additional, Nishioka, Akihito, additional, and Ogawa, Yasuhiro, additional

Published
2007
Full Text
View/download PDF

23. Clinical implications of preoperative chemoradiotherapy prior to laparoscopic surgery for locally advanced low rectal cancer.

Author

Kondo K, Shimbo T, Tanaka K, Yamamoto M, Narumi Y, Okuda J, and Uchiyama K

Abstract

The present study aimed to evaluate whether preoperative chemoradiotherapy (CRT) has any adverse effects on laparoscopic surgery (LS) for locally advanced low rectal cancer (LARC). The study was performed at the Osaka Medical College Hospital, and included patients who were operated on between July 2006 and December 2013. The short-term outcomes in 156 patients who underwent surgery for LARC following CRT were evaluated, of whom 152 underwent LS. Among the patients who were followed for >40 months, 77 patients (the CRT group) were compared with 39 patients who underwent LS without CRT (the surgery-alone group) for long-term outcomes. The total number of patients who received sphincter-preserving surgery was 74%. No positive longitudinal resection margins were identified, and only 1.3% had identifiable positive circumferential resection margins. The complication rate was 14%, and no serious complications occurred. There were no significant differences between the CRT and the surgery-alone groups in terms of the 5-year relapse-free survival rate (70.1 vs. 61.5%; P=0.81) or the 5-year overall survival rate (88.3 vs. 69.2%; P=0.06). However, the 5-year local recurrence-free survival rate was significantly improved in the CRT group patients (96.1 vs. 79.5%; P=0.009). In conclusion, our results have demonstrated that LS with preoperative CRT appears to be feasible and safe, and may have beneficial effects on local recurrence.

Published
2017
Full Text
View/download PDF

24. Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer.

Author

Yoshioka H, Shimbo T, Yoshida K, Yoshikawa N, Uesugi Y, Yamamoto K, Azuma H, and Narumi Y

Subjects
Adult, Aged, Antineoplastic Agents adverse effects, Chemoradiotherapy adverse effects, Chemoradiotherapy mortality, Cisplatin adverse effects, Female, Humans, Iliac Artery, Infusions, Intra-Arterial, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Proportional Hazards Models, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology, Antineoplastic Agents administration & dosage, Balloon Occlusion adverse effects, Balloon Occlusion mortality, Chemoradiotherapy methods, Cisplatin administration & dosage, Radiotherapy, Conformal adverse effects, Radiotherapy, Conformal mortality, Urinary Bladder Neoplasms therapy
Abstract

Aim: We present preliminary results from our clinical study evaluating the effectiveness of combination of radiotherapy with balloon-occluded arterial infusion (BOAI) and hemodialysis (HD) for bladder cancer., Patients and Methods: We investigated 134 patients with a median age of 67 years (range=38-88 years) and a median follow-up time of 31 months. According to the UICC classification, 89 patients were at clinical stage T2, 40 at T3, and 5 at T4. All patients received external-beam radiation therapy (EBRT) of 50 Gy to the whole pelvis with 10 Gy to the bladder as a boost. During EBRT, BOAI of cisplatin (CDDP) (100 mg/body) was administered from bilateral internal iliac arteries with simultaneous HD to prevent back-flow of CDDP into the systemic circulation., Results: Three-year local control and overall survival (OS) rates were 68% and 80%, respectively, and 3-year bladder preservation rate was 90%. Univariate and multivariate analysis showed that T stage and primary effect were significant prognostic factors for OS. In addition, primary effect was a significant prognostic factor for bladder preservation. None of the patients had grade 2 or more severe hematological toxicity. Late grade ≥3 genitourinary (GU) and gastrointestinal (GI) complications were observed in 6% and 2% of the patients, respectively., Conclusion: Combination of radiotherapy with BOAI and HD, associated with reduced hematological toxicity, may be regarded as a curative therapy for patients with bladder cancer. Late GU and GI complications were within acceptable limits. T stage is an important predictive factor for the outcome of this therapy., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results